Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer.

Senescence-modulating nanoparticles targeting P-selectin reduce fibrosis and enhance immunotherapy response in cancer models.

• Why it matters: Fibrotic tissue remodeling creates immunosuppressive environments that hinder effective cancer treatments, highlighting the need for targeted therapies against senescent cells.
• What they did: Researchers developed fucoidan-based nanoparticles that bind P-selectin to selectively target senescent-like cells, demonstrating antifibrotic and immunomodulatory effects in fibrotic tissues and tumors.
• The result: This approach reprogrammed immune environments, restored immune cell infiltration, and improved tumor sensitivity to immune checkpoint therapies, offering a versatile strategy for fibrosis and cancer treatment.